Biohaven Investor and Clinician Dinner in Philadelphia

May 7, 2019

Please join Biohaven for an informative Investor and Clinician dinner as leading experts discuss the advancement of the Biohaven NOJECTION™ CGRP antagnonist platform.

Guest Speakers:
Richard Lipton, MD
Albert Einstein College of Medicine Montefiore Headache Center

David Kudrow, MD
California Medical Clinic for Headache

Jelena Pavlovic, MD
Albert Einstein College of Medicine Montefiore Headache Center


Date:
Tuesday, May 7th, 2019
 
Time:
Registration: 6:30pm
Presentation & Dinner: 7:00pm
 

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Biohaven Pharmaceuticals, Inc [BHVN] US$3,657 MM MCap
NURTEC® ODT ap­proved in 1Q20. To­p­line re­sults ex­pect­ed 1Q20 in Ph 3 study of tro­r­ilu­zole for mi­graine pre­ven­tion. To­p­line re­sults ex­pect­ed 2Q20 in Ph 2/3 study of tro­r­ilu­zole for OCD. ~$600M to­tal in cash on hand, in­clud­ing re­cent $282.3M raise to sup­port NURTEC ODT launch. [more in­for­ma­tion]